The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET PRE-OPEN: Persimmon Sees Rise In Half Year Earnings

Tue, 21st Aug 2018 07:38

LONDON (Alliance News) - Stock prices in London are seen opening lower on Tuesday with US-China trade talks in focus, as Persimmon reported an increased profit for the first half. IG futures indicate the FTSE 100 index is to open down 18.36 points at 7,572.90. The blue chip index closed up 0.4% at 7,591.26 on Monday. In early UK corporate news, miner BHP Billiton paid out to shareholders above its policy level, with annual profit rising though short of consensus.For the 12 months to June, BHP is paying a "record" final dividend of 63 US cents a share, 17 cents above its policy of paying 50% of underlying attributable profit.The total dividend for BHP's financial year was 118 cents, far higher than the 83 cents paid out a year earlier and above analyst consensus of a 116 cents return.BHP's pretax profit rose to USD14.75 billion from USD11.14 billion the prior year, while underlying earnings before interest, tax, depreciation, and amortisation was up 20% to USD23.18 billion.Housebuilder Persimmon said it saw a strong first half of 2018 reflecting its commitment to delivery of high quality growth.For the half year to the end of June, revenue rose 5% to GBP1.84 billion from GBP1.75 billion last year and pretax profit was up 13% to GBP516.3 million from GBP457.4 million last year. New home sales increased 4% to 8,072 from 7,794 last year - with an additional 278 new homes delivered in the period.Persimmon said it returned surplus capital to shareholders of 125 pence per share in March 2018, in addition to the payment of 110 pence per share paid in July. The company added that it remained committed to return surplus capital of at least 235 pence per share for the next two years ending 2020, and 110 pence per share in 2021."The group has a robust platform to continue to deliver successful outcomes based on its high quality land bank, strong forward sales, excellent financial position, and experienced management team. We believe we are well positioned to deliver further high quality, sustainable growth," said Chief Executive Jeff Fairburn.Anglo-Swedish drugmaker AstraZeneca said its non-small-cell lung carcinoma drug Tagrisso has been approved in Japan as a first line treatment. "Tagrisso is already approved in Japan for the treatment of patients with EGFR T790M mutation-positive inoperable or recurrent NSCLC that is resistant to existing 1st-line EGFR-inhibitor medicines. Today's approval moves the use of Tagrisso to the 1st-line setting, replacing older medicines which, given the high prevalence of the EGFR mutation in Japan, offers an important new treatment option for these patients," said Dave Fredrickson, head of its Oncology unit. Gold miner Polymetal International reported strong earnings on the back of solid operational delivery in the first half of the year.For the half year to the end of June, revenue was up 16% to USD789.0 million from USD683.0 million last year and net earnings were up 46% to USD175.0 million from USD120.0 million the year before. Gold sales in the first half were up 17% at 445,000 ounces, although silver was down 2% at 12.1 million ounces.Polymetal declared an interim dividend of 0.17 cents, up 21% from 0.14 cents paid last year. "We expect stronger production and free cash flow generation for the second half and remain focused on steadily progressing our further growth pipeline, including full ramp-up of Kyzyl, while generating meaningful dividends to our shareholders," said Chief Executive Vitaly Nesis.The Japanese Nikkei 225 index closed up 0.1%. In China, the Shanghai Composite is up 1.4%, while the Hang Seng index in Hong Kong is up 0.6%.Asian stock markets are higher following the modest gains overnight on Wall Street amid optimism over US-China trade talks. The dollar declined after a report from Reuters said that US President Donald Trump accused China, as well as Europe, of manipulating their currencies and also said he was "not thrilled" with Federal Reserve Chair Jerome Powell for raising interest rates.In the US on Monday, Wall Street ended higher, with the Dow Jones Industrial Average up 0.4%, S&P 500 up 0.2% and Nasdaq Composite up 0.1%. The pound was up against the dollar quoted at USD1.2843 compared to USD1.2761 on Monday.Still to come in the economic calendar in Europe is UK public sector borrowing figures at 0930 BST.
More News
8 Feb 2024 08:59

LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend

(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.

Read more
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.